Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial ● Currently Recruiting Phase II NCT06977581

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma — Recruiting • Phase II • Respiratory / COPD / Asthma • NCT06977581.

📅 04 May 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Phase II
NCT ID
NCT06977581
Sponsor
Pfizer
Start
2025-05-20
ClinicaliQ Trial Snapshot
  • A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma — Recruiting • Phase II • Respiratory / COPD / Asthma • NCT06977581.
  • Treatment being tested: PF-07275315, an investigational medicine for moderate-to-severe asthma, with assessment of its safety profile and clinical efficacy in reducing breathing difficulties.
  • Patient eligibility: Adults with confirmed moderate-to-severe asthma diagnosis; typically requires documented airway obstruction, suboptimal control on current therapy, and absence of significant comorbidities that would compromise trial safety.
Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07275315) for the potential treatment of moderate-to-severe asthma. Asthma is a condition that makes it challenging to breathe, which negatively impacts the quality of life and functioning of people who are affected. This study is seeking participants who: * Are 18 to 70 years old * Have had moderate-to-severe asthma for at least 12 months that is not well controlled * Have been taking their regular maintenance treatment(s) for asthma over…

Eligibility Snapshot
  • : Must meet the following asthma criteria: 1. History of persistent, moderate-to-severe asthma for at least 12 months prior to screening. 2. Must have experienced at least 1 asthma exacerbation requiring treatment with systemic steroids (oral or parenteral) for 3 days or more within 12 months of the screening visit. 3. At least 2 of the 3 pre-bronchodilator FEV1 values collected in the run-in period and the mean of the of pre-bronchodilator FEV1 values collected in the run-in period are ≥30% to

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Digital technologies for applying algorithms to spirometry to support asthma and COPD diagnosis in primary care and community diagnostic centres: early-use assessment
Respiratory / COPD / Asthma · 02 Apr 2026
Digital spirometry algorithms can improve diagnostic accuracy for asthma and COPD in primary care and community diagnostic centres, potentially reducing unnecessary referrals…
View guideline →
Guideline
Digital technologies to support self-management of asthma: early-use assessment
Respiratory / COPD / Asthma · 05 May 2026
Use digital asthma self-management tools (apps, web platforms, wearables) as adjuncts to standard care to help patients monitor symptoms, track triggers, and…
View guideline →
Guideline
GINA 2024 Report: Global Strategy for Asthma Management and Prevention
Respiratory / COPD / Asthma · 31 Mar 2026
GINA 2024 reinforces no SABA-only treatment for any asthma severity: all patients should receive ICS-containing controller therapy or ICS-formoterol MART as first-line…
View guideline →
Guideline
Mepolizumab for Treating Severe Refractory Eosinophilic Asthma (NICE TA431)
Respiratory / COPD / Asthma · 27 Mar 2026
Initiate mepolizumab 100 mg subcutaneously once monthly only in adults with severe eosinophilic asthma inadequately controlled on high-dose inhaled corticosteroids plus long-acting…
View guideline →
Guideline
Asthma: Diagnosis, Monitoring and Chronic Asthma Management (NICE NG80/BTS)
Respiratory / COPD / Asthma · 25 Mar 2026
Diagnose asthma only with objective evidence of reversible airflow obstruction or bronchial hyperresponsiveness, not on clinical symptoms alone Initiate Step 2 treatment…
View guideline →
Guideline
Bronchiectasis (non-CF): Diagnosis and Management (NICE NG117)
Respiratory / COPD / Asthma · 27 Mar 2026
Suspect bronchiectasis in patients presenting with chronic productive cough or recurrent respiratory infections and refer for High-Resolution CT chest imaging; investigate all…
View guideline →